2. Apoptosis Immunology/Inflammation Stem Cell/Wnt MAPK/ERK Pathway Protein Tyrosine Kinase/RTK PI3K/Akt/mTOR Epigenetics
  3. Pyroptosis NOD-like Receptor (NLR) ERK FGFR AMPK
  4. Kanglexin

Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.

For research use only. We do not sell to patients.

Kanglexin Chemical Structure

Kanglexin Chemical Structure

CAS No. : 2228847-12-7

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Kanglexin Related Antibodies

Top Publications Citing Use of Products

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms
NLRP3 NLRP1 NOD1 NOD2

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All FGFR Isoform Specific Products:

View All Isoforms
FGFR FGFR1 FGFR2 FGFR3 FGFR4 FGF21

View All AMPK Isoform Specific Products:

View All Isoforms
NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis[1][2][3][4].

IC50 & Target[1]

NLRP3

 

In Vitro

Kanglexin (10-20 μM; 24 h) inhibits pyroptosis of cardiomyocytes treated with hypoxia or LPS (HY-D1056)[1].
Kanglexin (5-20 μM; 24 h) reduces lipid levels in oleic acid (HY-N1446) treated HepG2 cells through AMPK/SREGBP-2/PCSK9/LDLR signaling pathway[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Kanglexin Related Antibodies

Western Blot Analysis[1]

Cell Line: LPS (HY-D1056) treated neonatal mouse ventricular cardiomyocytes
Concentration: 10 μM
Incubation Time: 24 h
Result: Inhibited the levels of NLRP3 and the pyroptosis-related proteins mature IL-1β and IL-18.
In Vivo

Kanglexin (20-40 mg/kg; oral gavage; 7 days) has an ameliorative effect in the myocardial infarction mouse model[1].
Kanglexin (20-80 mg/kg; oral administration; 2 weeks) has an ameliorative effect in the hyperlipidemia rat model[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male C57BL/6 mice aged 8 weeks old (20 ± 2 g) with myocardial infarction (MI) model[1]
Dosage: 20 and 40 mg/kg
Administration: Oral gavage (i.g.); 7 days
Result: Reduced myocardial injury in MI mice.
Effectively inhibited pyroptosis processes in the mouse hearts with MI.
Attenuated the activation of the NLRP3 inflammasome upon MI in mouse hearts.
Animal Model: High fat diet treated Sprague-Dawley rats[2]
Dosage: 20, 40 and 80 mg/kg
Administration: Oral administration (p.o.); 2 weeks
Result: Had prominent effects on reducing blood lipids, hepatic lipid accumulation, body weight and the ratio of liver weight/body weight.
Molecular Weight

398.36

Formula

C21H18O8
CAS No.
SMILES

O=C1C2=C(C(C3=C(C=C(C)C=C13)O)=O)C(O)=CC(OC(CCC(OCC)=O)=O)=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Kanglexin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Kanglexin2228847-12-7PyroptosisNOD-like Receptor (NLR)ERKFGFRAMPKExtracellular signal regulated kinasesFibroblast growth factor receptorAMP-activated protein kinasemyocardial infarction modelhyperlipidemia modelcardiomyocytesHepG2 cellsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Kanglexin
Cat. No.:
HY-164853
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.